Pangaea Oncology is transitioning from a services-based company to a technology product company, according to a recent statement. The company anticipates surpassing 6,000 recent oncology patients and generating over 90,000 total visits in 2025, building on strong growth in surgical activity, clinical trials, and diagnostics. This shift comes as Pangaea prepares to close a capital increase, which will fuel investment in its laboratory and the development of high-precision oncology products and services.
The company highlighted several key strengths driving its success, including a leadership position in attracting top talent – with six of the ten highest-ranked oncologists in Spain affiliated with its group – and a substantial patient volume exceeding 5,500 new oncology cases annually. Pangaea also boasts leading diagnostic capabilities, having been the first laboratory in Spain accredited for molecular diagnostics in conventional biopsy (2009), liquid biopsy (2016), and Next Generation Sequencing (NGS) (2020). The company currently has over 200 preclinical models available to its clients.
Pangaea Oncology’s success is also attributed to its access to new drugs, with more than 200 active clinical trials, and its ability to generate innovative ideas that translate into clinical practice. The company’s model focuses on combining clinical assistance with active participation in scientific forums to drive continuous learning and innovation. This approach is designed to improve patient outcomes and contribute to advancements in cancer treatment.
Looking ahead to 2027, Pangaea plans to build a technological infrastructure to further enhance its contractual capabilities, essentially creating a technology incubator. This will enable the generation of new ideas and a substantial increase in its contract portfolio, leveraging near real-time data – including genomic information – and predictive analytics. The company internally refers to this evolution as “Pangaea 2.0.”
Javier Rivela, CEO of Pangaea Oncology, stated, “In 2025 we have confirmed that the Pangaea Oncology model works.” He added that the company expects to see accelerated organic growth and increased profitability through the development of a product platform alongside its existing clinical and assistance model.
